Why the study?
The molecular basis of inflammation in arrhythmogenic cardiomyopathy remains under-investigated, and whether inflammation is a primary event or a secondary response to cardiomyocyte death is unclear.
Understanding whether inflammation is a primary driver or secondary event in arrhythmogenic cardiomyopathy could open novel therapeutic avenues like anti-inflammatory therapy.
Distinguishing primary vs secondary inflammation in arrhythmogenic cardiomyopathy is needed before anti-inflammatory trials; leaves open therapeutic efficacy pending prospective data.
Arrhythmogenic cardiomyopathy (ACM) is a rare inherited cardiac disease characterized by arrhythmia and progressive fibro-fatty replacement of the myocardium, which leads to heart failure and sudden cardiac death. Inflammation contributes to disease progression, and it is characterized by inflammatory cell infiltrates in the damaged myocardium and inflammatory mediators in the blood of ACM patients. However, the molecular basis of inflammatory process in ACM remains under investigated and it is unclear whether inflammation is a primary event leading to arrhythmia and myocardial damage or it is a secondary response triggered by cardiomyocyte death. Here, we provide an overview of the proposed players and triggers involved in inflammation in ACM, focusing on those studied using in vivo and in vitro models. Deepening current knowledge of inflammation-related mechanisms in ACM could help identifying novel therapeutic perspectives, such as anti-inflammatory therapy.
No takes yet. Share an insight, caveat, or question.
Meraviglia et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: